A citation-based method for searching scientific literature

Michele Ceribelli, Priscilla N Kelly, Arthur L Shaffer, George W Wright, Wenming Xiao, Yibin Yang, Lesley A Mathews Griner, Rajarshi Guha, Paul Shinn, Jonathan M Keller, Dongbo Liu, Paresma R Patel, Marc Ferrer, Shivangi Joshi, Sujata Nerle, Peter Sandy, Emmanuel Normant, Craig J Thomas, Louis M Staudt. Proc Natl Acad Sci U S A 2014
Times Cited: 128



Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait, Carmen Kahatt, Bruno Quesnel, Mauricette Michallet, Christian Recher, François Lokiec, Claude Preudhomme, Hervé Dombret. Lancet Haematol 2016
Times Cited: 270




List of shared articles



Times cited

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, Khanh T Do, Caron A Jacobson, Ulka Vaishampayan, Amy Weise, Paolo F Caimi, Joseph Paul Eder, Christopher A French,[...]. Br J Cancer 2021
26

BET Proteins as Attractive Targets for Cancer Therapeutics.
Joanna Sarnik, Tomasz Popławski, Paulina Tokarz. Int J Mol Sci 2021
1

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
V Moreno, J M Sepulveda, M Vieito, T Hernández-Guerrero, B Doger, O Saavedra, O Ferrero, R Sarmiento, M Arias, J De Alvaro,[...]. Ann Oncol 2020
15

Targeting BET bromodomain proteins in cancer: The example of lymphomas.
Filippo Spriano, Anastasios Stathis, Francesco Bertoni. Pharmacol Ther 2020
16

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, Chiara Tarantelli, Federica Melle, Giovanna Motta, Valdemar Priebe, Andrea Rinaldi, Gaetanina Golino, Afua Adjeiwaa Mensah,[...]. Blood Adv 2020
12

B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
Stefano Ratti, Annalisa Lonetti, Matilde Y Follo, Francesca Paganelli, Alberto M Martelli, Francesca Chiarini, Camilla Evangelisti. Cancers (Basel) 2020
5

Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).
Dongfeng Zeng, Aakash Desai, Fangfang Yan, Tiejun Gong, Haige Ye, Makhdum Ahmed, Krystle Nomie, Jorge Romaguera, Richard Champlin, Shaoying Li,[...]. Am J Clin Oncol 2019
8


BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses.
Anup Dey, Wenjing Yang, Anne Gegonne, Akira Nishiyama, Richard Pan, Ryoji Yagi, Alex Grinberg, Fred D Finkelman, Karl Pfeifer, Jinfang Zhu,[...]. EMBO J 2019
57

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Talal Khan, Neil Senzer, John Nemunaitis. Future Sci OA 2019
142

Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
Francesco Bertoni, Anastasios Stathis. Curr Opin Hematol 2019
3

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
175

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.
Yunlu Jia, Wee-Joo Chng, Jianbiao Zhou. J Hematol Oncol 2019
27


BET Proteins as Targets for Anticancer Treatment.
Anastasios Stathis, Francesco Bertoni. Cancer Discov 2018
206

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Hatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, Zachary A Hing, James S Blachly, Bonnie Harrington, Shaneice Mitchell, Nicole R Grieselhuber, Katie Williams, Tzung-Huei Lai,[...]. Cancer Discov 2018
61

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Daniel Gerlach, Ulrike Tontsch-Grunt, Anke Baum, Johannes Popow, Dirk Scharn, Marco H Hofmann, Harald Engelhardt, Onur Kaya, Janina Beck, Norbert Schweifer,[...]. Oncogene 2018
42

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
Afua A Mensah, Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, Riccardo Bomben, Elena Bernasconi, Domenico Zito, Andrea Lampis, Jens C Hahne, Andrea Rinaldi,[...]. Haematologica 2018
8

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.
K Tomska, R Kurilov, K S Lee, J Hüllein, M Lukas, L Sellner, T Walther, L Wagner, M Oleś, B Brors,[...]. Sci Rep 2018
15

NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
Kotaro Hishiki, Masaharu Akiyama, Yumi Kanegae, Koji Ozaki, Miyuki Ohta, Emi Tsuchitani, Ken Kaito, Hisashi Yamada. Leuk Res 2018
9

HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
Xiaoyu Lin, Xiaoli Huang, Tamar Uziel, Paul Hessler, Daniel H Albert, Lisa A Roberts-Rapp, Keith F McDaniel, Warren M Kati, Yu Shen. Mol Cancer Ther 2017
34

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Mai H Bui, Xiaoyu Lin, Daniel H Albert, Leiming Li, Lloyd T Lam, Emily J Faivre, Scott E Warder, Xiaoli Huang, Denise Wilcox, Cherrie K Donawho,[...]. Cancer Res 2017
69

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Elena Bernasconi, Eugenio Gaudio, Pascale Lejeune, Chiara Tarantelli, Luciano Cascione, Ivo Kwee, Filippo Spriano, Andrea Rinaldi, Afua A Mensah, Elaine Chung,[...]. Br J Haematol 2017
25

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Eugenio Gaudio, Chiara Tarantelli, Maurilio Ponzoni, Elodie Odore, Keyvan Rezai, Elena Bernasconi, Luciano Cascione, Andrea Rinaldi, Anastasios Stathis, Eugenia Riveiro,[...]. Oncotarget 2016
18